Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Quadrivalent influenza split vaccine (Changchun Sponsor Institute of Biological Products)
- Development stage
- Phase 1
- Lead developer
- Changchun Institute of Biological Products
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
A quadrivalent inactivated split-virion influenza vaccine designed to provide protection against four seasonal influenza virus strains. It includes antigens from two influenza A subtypes (H1N1 and H3N2) and two influenza B lineages (Victoria and Yamagata). Developed in collaboration with the Jiangsu Province Centers for Disease Control and Prevention and manufactured by Changchun Sponsor Institute of Biological Products, the vaccine is administered via intramuscular injection. It is intended to stimulate the production of hemagglutination-inhibition (HI) antibodies to prevent infection and reduce the severity of seasonal influenza, particularly in pediatric populations.
- Other names
- Quadrivalent inactivated influenza vaccineInfluenza virus split vaccine
02
Targets
HA (Hemagglutinin)
Beyond the preview
Go deeper on Quadrivalent influenza split vaccine (Changchun Sponsor Institute of Biological Products).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Quadrivalent influenza split vaccine (Changchun Sponsor Institute of Biological Products).